J.M. Sánchez-Torres

1.2k total citations
21 papers, 772 citations indexed

About

J.M. Sánchez-Torres is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, J.M. Sánchez-Torres has authored 21 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Epidemiology. Recurrent topics in J.M. Sánchez-Torres's work include Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (5 papers). J.M. Sánchez-Torres is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (5 papers). J.M. Sánchez-Torres collaborates with scholars based in Spain, United States and United Kingdom. J.M. Sánchez-Torres's co-authors include Rámón Colomer, Arántzazu Alfranca, Jacobo Rogado, Ana M. Ramos‐Leví, Nuria Romero-Laorden, O. Donnay, Vilma Pacheco-Barcía, Javier Aspa, Dolores Isla and Magdalena Adrados and has published in prestigious journals such as Clinical Cancer Research, Annals of Oncology and European Respiratory Journal.

In The Last Decade

J.M. Sánchez-Torres

21 papers receiving 757 citations

Peers

J.M. Sánchez-Torres

ONCOL

PRM

IMMUN

Maria Bassanelli Italy

Ramón Palmero Spain

Delphine Topart France

Ivana Sullivan Spain

Katherine A. Scilla United States

María Gión Spain

Shinichiro Shimamatsu Japan

Angel Qin United States

Daniel Lee South Korea

Gen Lin China

Maria Bassanelli Italy

J.M. Sánchez-Torres

419 ×0.7

ONCOL

326 ×0.8

PRM

99 ×0.7

68 ×0.7

57 ×0.6

IMMUN

Citations per year, relative to J.M. Sánchez-Torres J.M. Sánchez-Torres (= 1×) peers Maria Bassanelli

Countries citing papers authored by J.M. Sánchez-Torres

Since Specialization

Citations

This map shows the geographic impact of J.M. Sánchez-Torres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.M. Sánchez-Torres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.M. Sánchez-Torres more than expected).

Fields of papers citing papers by J.M. Sánchez-Torres

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.M. Sánchez-Torres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.M. Sánchez-Torres. The network helps show where J.M. Sánchez-Torres may publish in the future.

Co-authorship network of co-authors of J.M. Sánchez-Torres

This figure shows the co-authorship network connecting the top 25 collaborators of J.M. Sánchez-Torres. A scholar is included among the top collaborators of J.M. Sánchez-Torres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.M. Sánchez-Torres. J.M. Sánchez-Torres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rogado, Jacobo, Fernando Campo del Pozo, Kevin Troulé, et al.. (2024). The role of the CXCL12/CXCR4 axis in the immunotherapy of non-small cell lung cancer. Clinical & Translational Oncology. 27(7). 2970–2981. 2 indexed citations

Rogado, Jacobo, Fernando Campo del Pozo, Kevin Troulé, et al.. (2022). Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. Cancers. 14(12). 2898–2898. 8 indexed citations

Rogado, Jacobo, Fernando Campo del Pozo, Kevin Troulé, et al.. (2022). Excess weight and anti-PD-1 immune checkpoint inhibitor’s outcomes in non-small cell lung cancer. Clinical & Translational Oncology. 24(11). 2241–2249. 1 indexed citations

Garrido, Pilar, Luis Paz‐Ares, Margarita Majem, et al.. (2021). LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 10(17). 5878–5888. 14 indexed citations

Sánchez-Torres, J.M., et al.. (2021). Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic. Frontiers in Psychology. 12. 755965–755965. 16 indexed citations

Sánchez‐Alonso, Santiago, et al.. (2020). A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. Journal for ImmunoTherapy of Cancer. 8(2). e001187–e001187. 48 indexed citations

Rogado, Jacobo, Nuria Romero-Laorden, J.M. Sánchez-Torres, et al.. (2020). Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. OncoImmunology. 9(1). 1751548–1751548. 32 indexed citations

Rogado, Jacobo, J.M. Sánchez-Torres, Nuria Romero-Laorden, et al.. (2019). Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients. European Journal of Cancer. 109. 21–27. 192 indexed citations

Zugazagoitia, Jon, Eloísa Jantus‐Lewintre, Dolores Isla, et al.. (2019). Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer. 134. 72–78. 21 indexed citations

10.

Ramos‐Leví, Ana M., Jacobo Rogado, J.M. Sánchez-Torres, Rámón Colomer, & Mónica Marazuela. (2019). Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinología Diabetes y Nutrición (English ed ). 66(1). 26–34. 1 indexed citations

11.

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations

12.

Rogado, Jacobo, R. Mondéjar, Nuria Romero-Laorden, et al.. (2018). 190P Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of nivolumab outcome and toxicity in NSCLC?. Journal of Thoracic Oncology. 13(4). S114–S114. 1 indexed citations

13.

Ramos‐Leví, Ana M., Jacobo Rogado, J.M. Sánchez-Torres, Rámón Colomer, & Mónica Marazuela. (2018). Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinología Diabetes y Nutrición. 66(1). 26–34. 17 indexed citations

14.

Rogado, Jacobo, R. Mondéjar, O. Donnay, et al.. (2018). 187P Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response. Journal of Thoracic Oncology. 13(4). S112–S112. 2 indexed citations

15.

Karachaliou, Niki, Andrés F. Cardona, María González Cao, et al.. (2017). P2.02-034 PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib. Journal of Thoracic Oncology. 12(11). S2110–S2111. 1 indexed citations

16.

Scagliotti, Giorgio V., Igor Bondarenko, Fiona Blackhall, et al.. (2014). Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Annals of Oncology. 26(3). 497–504. 51 indexed citations

17.

Sánchez-Torres, J.M., Santiago Viteri, Miguel Ángel Molina‐Vila, & Rafael Rosell. (2013). BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.. PubMed. 2(3). 244–50. 40 indexed citations

18.

Porta, R., J.M. Sánchez-Torres, Luis Paz‐Ares, et al.. (2010). Brain metastases from lung cancer responding to erlotinib: the importance ofEGFRmutation. European Respiratory Journal. 37(3). 624–631. 247 indexed citations

19.

Viñolas, Núria, Mariano Provencio, Noemı́ Reguart, et al.. (2010). Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer. 71(2). 191–198. 39 indexed citations

20.

Dickgreber, Nicolas, Jens Benn Sørensen, Tine Schytte, et al.. (2010). Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid. Clinical Cancer Research. 16(10). 2872–2880. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact